NTILF (Neurotech International) Dividends Received: $0.00 Mil (TTM As of Dec. 2025)


NTILF Neurotech International Ltd NTILF
34 GF Score
Price $0.00
! 1 Warning Sign
View Full Analysis

What is Neurotech International Dividends Received?

Neurotech International NTILF 34 Dividends Received is $0.00 Mil as of Dec. 2025. GuruFocus rates NTILF with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

Neurotech International's Dividends Received for the six months ended in Dec. 2025 was $0.00 Mil.

Neurotech International's Dividends Received for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.

Neurotech International Dividends Received Related Terms

Neurotech International Dividends Received Historical Data

* Premium members only.

The historical data trend for Neurotech International's Dividends Received can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurotech International Dividends Received Chart

Neurotech International Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Dividends Received
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Neurotech International Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Dividends Received Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NTILF
34GF Score
Neurotech International Ltd NTILF
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurotech International Dividends Received Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Dividends Received represents dividend received on the investment in the direct cash flow method.

Dividends Received for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Dividends Received →
What does a Dividends Received of $0.00 Mil mean?
Neurotech International (NTILF) has a Dividends Received of $0.00 Mil as of Dec. 2025. Dividends Received represents dividend received on the investment in direct cash flow method. View historical data for Neurotech International and its competitors.
Is Neurotech International's Dividends Received too high?
Neurotech International's current Dividends Received is $0.00 Mil. Overall, Neurotech International has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Neurotech International's Dividends Received compare to VRTX and REGN?
Neurotech International's Dividends Received of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends Received for a Biotechnology company?
A good Dividends Received depends on the Biotechnology industry context. However, Dividends Received should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends Received mean?
A high Dividends Received can signal that a stock is expensive relative to its fundamentals. Dividends Received represents dividend received on the investment in direct cash flow method. View historical data for Neurotech International and its competitors. Neurotech International's current Dividends Received is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurotech International stock overvalued right now?
Neurotech International (NTILF) has a current Dividends Received of $0.00 Mil. The current Dividends Received is $0.00 Mil. Neurotech International's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends Received calculated?
Dividends Received is calculated from a company's financial statements. For Neurotech International (NTILF), the current Dividends Received is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurotech International Business Description

Other Exchanges NTI:Australia
Address 55 Collins Street, Suite 102, Level 1, Melbourne, VIC, AUS, 3000
Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.
34GF Score

Get the complete analysis for NTILF

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price